Last reviewed · How we verify
Adreview (iobenguane (123I))
Adreview (generic name: iobenguane (123I)) is a Radioactive Diagnostic Agent drug developed by GE HealthCare. It is currently FDA-approved (first approved 2008).
Adreview works by binding to specific cells or tissues in the body, allowing for imaging and diagnosis.
At a glance
| Generic name | iobenguane (123I) |
|---|---|
| Sponsor | GE HealthCare |
| Drug class | Radioactive Diagnostic Agent |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2008 |
Mechanism of action
Iobenguane is similar in structure to the antihypertensive drug guanethedine and to the neurotransmitter norepinephrine (NE). Iobenguane is, therefore, largely subject to the same uptake and accumulation pathways as NE. Iobenguane is taken up by the NE transporter in adrenergic nerve terminals and stored in the presynaptic storage vesicles. Iobenguane accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen and lungs as well as tumors derived from the neural crest. By labeling iobenguane with the isotope iodine 123, it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates.
Approved indications
Common side effects
- Radioactive contamination
- Thyroid uptake of radioiodide contaminant
Key clinical trials
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (PHASE2)
- Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- MIBG in Aging and Neurologic Disorders (PHASE4)
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors (EARLY_PHASE1)
- Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR
- Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adreview CI brief — competitive landscape report
- Adreview updates RSS · CI watch RSS
- GE HealthCare portfolio CI
Frequently asked questions about Adreview
What is Adreview?
How does Adreview work?
Who makes Adreview?
What is the generic name of Adreview?
What drug class is Adreview in?
When was Adreview approved?
What development phase is Adreview in?
What are the side effects of Adreview?
Related
- Drug class: All Radioactive Diagnostic Agent drugs
- Manufacturer: GE HealthCare — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing